LL-37 Peptide Market 2026: Antimicrobial Resistance Drives 12.3% CAGR Growth in Wound Care & Immunotherapy Applications
Published: 9 7 月, 2026 12:04
Author: Deepa Wagner
Abstract: Driven by escalating antimicrobial resistance, the LL-37 peptide market is projected to achieve a 12.3% CAGR through 2026, primarily in wound care and immunotherapy. This analysis compares leading brands (e.g., Bachem, CPC Scientific) on purity (>95%) and endotoxin levels (<0.1 EU/mg). Key advantages include broad-spectrum activity and immunomodulation; limitations are high production costs and enzymatic instability. Applications span chronic wounds, oncology, and acne. Market trends favor GMP-certified facilities and lyophilized logistics for stability. Selection criteria prioritize purity certificates, batch consistency, and third-party bioassay validation.